The company is part of a group that has been developing and manufacturing innovative hypoxic-hyperoxic therapy solutions since 2006. It operates its own production facilities using domestic components, has trading houses, a well-developed dealer network and an expanding export direction. The company also runs service and educational centers and is ISO-certified.

The OXYTERRA device for producing hypoxic, hyperoxic and normoxic gas mixtures is used for the prevention, treatment and rehabilitation of cardiovascular, bronchopulmonary and neurological diseases, as well as for health preservation, prolonging active longevity, rejuvenation and weight management. Hypoxic-hyperoxic therapy is a physical, non-pharmacological method, with its effectiveness supported by the 2019 Nobel Prize in Medicine for the discovery of cellular adaptation mechanisms to oxygen.

The key advantage of OXYTERRA is its multi-mode functionality, which enables a personalized approach to each patient's therapy. The device allows for the creation and adjustment of treatment protocols during the procedure, taking into account the patient's medical history, current physical condition, pulse and oxygen saturation levels through biofeedback. In 2023, four new device modifications (Basic, Cardio, Sport, Pro) were released to personalize OXYTERRA therapy, increase treatment effectiveness and simplify the operator’s work. The device requires no consumables other than a mask with a filter, and the low cost of procedures allows for a return on investment within 7 months.